ResMed announces agreement to sell MatrixCare business
Sharpens focus on high-growth sleep and connected care markets.
See the latest news and media coverage for ResMed. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company for sleep and respiratory care
resmed.comLast updated
In short: ResMed reported strong Q3 2026 financial growth, completed a $340 million acquisition of Noctrix Health, and announced a CFO transition.
Sharpens focus on high-growth sleep and connected care markets.
The deal adds Nidra TOMAC therapy for Restless Legs Syndrome.
Mick Farrell highlights AI for personalized sleep experiences via Smart Comfort and DAWN. GLP-1 therapies boost sleep apnea diagnosis and CPAP engagement for 2.1+ million patients.
The certification, granted after an independent audit, confirms compliance with strict cybersecurity requirements to protect systems and patient data.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings...
RBC Capital Markets on Thursday downgraded ResMed (RMD) to Sector Perform from Outperform and lowered its price target to $234 from $276, arguing that the...
The FDA issued an early alert warning customers of potential issues with certain Resmed (NYSE:RMD) ventilator systems.
Our stock picking expert says ResMed is a quality business now facing two new headwinds. Here's what it has to overcome.
Track ResMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ResMed and other trending companies.